USPTO Examiner BOECKELMAN JACOB A - Art Unit 1655

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18972246TRADITIONAL CHINESE HERBAL COMPOSITION FOR TREATMENT OF BACTERIAL VAGINOSIS AND PREPARATION METHOD THEREOFDecember 2024February 2025Allow200NoNo
18669326HEALTH BENEFITING COMPOSITIONS OF DAILY NUTRITION AND METHODS OF USE THEREOFMay 2024January 2026Allow2011NoNo
18615843HEMP COMPOSITIONS AND METHODS OF MAKING THE SAMEMarch 2024September 2025Abandon1801NoNo
18403978BOTANICAL ANTIVIRAL NUTRITIONAL SUPPLEMENTJanuary 2024August 2025Abandon1910NoNo
18528030NUTRITION-BASED METHOD FOR MANAGING ANIMAL BEHAVIORDecember 2023November 2025Abandon2420NoNo
18467250TRADITIONAL CHINESE MEDICINE OINTMENT FOR PREVENTING AND TREATING MASTITIS IN DAIRY COWS, AND PREPARATION METHOD THEREOFSeptember 2023November 2024Allow1421NoNo
18446315COMBINED FUNGAL COMPOSITION FOR MODULATING AN INFLAMMATORY RESPONSEAugust 2023January 2026Allow2910NoNo
18326763COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY RESPONSEMay 2023January 2026Allow3110NoNo
18141249Production of Ethanol-free Vanilla ExtractsApril 2023February 2025Allow2111YesNo
18307570BEETROOT-CONTAINING COMPOSITIONApril 2023March 2024Allow1101YesNo
18129647METHOD AND COMPOSITION FOR PRODUCTION OF A PHYTONUTRIENT IN A MICROBIOMEMarch 2023January 2025Abandon2111NoNo
18126519COMPOSITIONS COMPRISING FUCOXANTHIN AND USE THEREOF IN REDUCTION OF FAT ACCUMULATION IN CELLSMarch 2023May 2025Abandon2510NoNo
18156431HERBAL COMPOSITION FOR TREATMENT OF ACIDITY AND INDIGESTION PROBLEMJanuary 2023July 2024Abandon1811NoNo
18097222WHOLE CANNABIS PRODUCT COMPOSITIONS AND METHODS OF MANUFACTURE WITHOUT SPECIFIC DECARBOXYLATION OF THE WHOLE PLANT CONSTITUENTSJanuary 2023February 2026Abandon3710NoNo
18089896COMPOSITIONS COMPRISING THEANINE, MAGNOLIA, AND PHELLODENDRONDecember 2022June 2024Allow1802YesNo
18087842IMMUNITY-BOOSTING AGENT, IMMUNO-THERAPEUTIC ANTI-CANCER AGENT, AND ANTI-CANCER THERAPY ADVERSE EFFECT MITIGATING AGENT CONTAINING ANTHOCYANIN-FUCOIDAN COMPLEX AS ACTIVE INGREDIENTDecember 2022August 2025Allow3230NoNo
18076147Pharmaceutical Composition Comprising CannabinoidDecember 2022September 2025Abandon3420NoNo
18073538REPELLANT FORMULATION AND METHODDecember 2022March 2025Allow2820YesNo
18073535REPELLANT FORMULATION AND METHODDecember 2022March 2025Allow2820YesNo
18070342SKIN BENEFIT COMPOSITIONS CONTAINING FERMENTED EXTACT OF A. MONTANANovember 2022August 2025Abandon3310NoNo
18055767PLATELET DERIVED EXTRACELLULAR VESICLESNovember 2022December 2025Abandon3710NoNo
17986621METHOD FOR PREPARING MUSHROOM ANTIBACTERIAL AGENT AND ANTIBACTERIAL AGENT MADE THEREFROMNovember 2022January 2026Allow3810NoNo
18053767HERBAL COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING SARS-COV-2 VIRUS INFECTIONNovember 2022December 2025Allow3711YesNo
17923496PREPARATION METHOD OF A COLLOIDAL SYSTEM OF STABILISATION AND CONTROLLED RELEASE OF ROYAL JELLY COMPONENTS FOR VARIOUS USESNovember 2022August 2025Allow3410NoNo
17977311COMPOSITIONS AND METHODS FOR SKIN RENEWALOctober 2022October 2025Abandon3541NoNo
17966912PROCESS FOR PRESERVING THE HUSK AND USE OF RAMBUTAN (NEPHELIUM LAPPACEUM) IN FOOD PRODUCTSOctober 2022April 2024Abandon1810NoNo
17966924PROCESS FOR PRESERVING THE HUSK AND USE OF RAMBUTAN (NEPHELIUM LAPPACEUM) IN FOOD PRODUCTSOctober 2022July 2024Abandon2110NoNo
17964100SERUM EXOSOME WITH HIGH OSTEOGENESIS AND HIGH ANGIOGENESIS, PREPARATION METHOD, AND APPLICATION THEREOFOctober 2022January 2026Allow4011NoNo
17963888PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GYNECOLOGICAL DISEASES CONTAINING SARCODON ASPRATUS EXTRACTS AS ACTIVE INGREDIENTOctober 2022September 2023Allow1100NoNo
17960503USE OF POLYPHENOL CONTAINING SUGAR CANE EXTRACTS FOR PREVENTING, IMPROVING OR TREATING A SKIN CONDITIONOctober 2022March 2025Allow3031NoNo
17907750BOVINE MILK EXOSOME PRODUCTS AND METHODS, NUTRITIONAL COMPOSITIONS, AND THERAPEUTIC METHODSSeptember 2022October 2025Abandon3601NoNo
17933534Method for Improving Eye ConditionSeptember 2022January 2026Allow4030YesNo
17912633COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NON-MALIGNANT RESPIRATORY DISEASESeptember 2022July 2025Abandon3401NoNo
17947012TOPICAL COMPOSITIONS FOR ENHANCING A MAN'S SEXUAL RESPONSIVENESS AND PERFORMANCESeptember 2022June 2024Abandon2101NoNo
17898017METHODS FOR ENHANCING SLEEP QUALITYAugust 2022August 2024Abandon2330NoNo
17819705BOTANICAL ANTIVIRAL NUTRITIONAL SUPPLEMENTAugust 2022July 2024Abandon2311NoNo
17885579TRADITIONAL CHINESE MEDICINE EYE DROPS AND THE PREPARATION METHOD THEREOFAugust 2022April 2024Allow2011YesNo
17759122PLANT-BASED COMPOSITION IN A FORM SUITABLE FOR TOPICAL ADMINISTRATION AND ASSOCIATED PRODUCTION METHODJuly 2022May 2025Abandon3401NoNo
17868704COMPOSITION FOR ENHANCING IMMUNITY OR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES BY USING GOJI BERRIES, MULBERRIES AND JUJUBESJuly 2022July 2023Allow1211YesNo
17860079TIBETAN FOUR-INGREDIENT LUNG-CLEARING MIXTURE AND APPLICATION THEREOF IN PREPARING MEDICATION FOR TREATING RESPIRATORY DISEASESJuly 2022January 2025Abandon3120NoNo
17859028TRADITIONAL CHINESE MEDICINE COMPOUND COMPOSITION WITH EFFECT OF IMPROVING MALE SEXUAL FUNCTION AND APPLICATION THEREOFJuly 2022July 2024Abandon2420NoNo
17856956Hepatoprotective Effects of Palauan Folk MedicineJuly 2022July 2024Abandon2420YesNo
17780590Composition Containing Black Ginger Extract and Composition for Oral AdministrationMay 2022December 2025Abandon4220YesNo
17756425NOVEL COMPOSITION FOR REDUCING STRESS DISORDERSMay 2022December 2025Abandon4311NoNo
17779680COMPOSITION FOR PREVENTING OR TREATING HYPERTENSIONMay 2022April 2025Allow3511NoNo
17777595COMPOSITION, COMPRISING VINEGAR PICKLED EGG AS ACTIVE INGREDIENT, FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DIABETIC FOOT ULCERMay 2022August 2025Abandon3910NoNo
17725587Honey FoamApril 2022March 2024Abandon2301NoNo
17770048PROCESS FOR THE PRODUCTION OF TAMARIND EXTRACTApril 2022June 2025Abandon3710NoNo
17721908COMPOSITION OF MATTER AND METHODS FOR A FECAL-DERIVED STERILIZED PREBIOTIC AND POSTBIOTICApril 2022March 2025Allow3851YesNo
17767492Use of Liriodendron Chinense (Hemsl.) Sarg. or Extract thereof in the Preparation of Medicament for Reducing Serum Uric Acid Level and Preventing and Treating Uric Acid NephropathyApril 2022December 2025Allow4420YesNo
17767604Composition For Preventing Or Treating Neurodegenerative Diseases Containing Mixed Herbal Extract Of Genkwae Flos, Clematidis Radix, And Gastrodiae RhizomaApril 2022May 2025Abandon3720NoNo
17706270HEALTH BENEFITING COMPOSITIONS OF DAILY NUTRITION AND METHODS OF USE THEREOFMarch 2022February 2024Allow2321NoNo
17640677THERAPEUTIC AGENT FOR MYOCARDITISMarch 2022June 2025Abandon3910NoNo
17685171COMPOSITIONS FOR IMPROVING EYE HEALTH AND METHODS OF MAKING AND USING THEREOFMarch 2022December 2025Abandon4511NoNo
17637915COMPOSITION FOR AMELIORATING PREMENSTRUAL SYNDROME SYMPTOMS, INCLUDING CHRYSANTHEMUM ZAWADSKII EXTRACTFebruary 2022October 2024Allow3230YesNo
17588211SYSTEMS AND METHODS FOR PRODUCING A KAVA LIQUID DIETARY SUPPLEMENTJanuary 2022April 2025Abandon3801NoNo
17631320PREPARATION COMPRISING OMEGA-3 FATTY ACID SALTS AND EXTRACTS OF GUM RESINS FROM BOSWELLIA SPECIESJanuary 2022January 2025Allow3510YesNo
17587535TREATMENT OF AGING OR UV-DAMAGED SKINJanuary 2022March 2025Abandon3801NoNo
17585612METHOD FOR IMPROVING BODY SHAPE AND IMPROVING SKIN CONDITION USING NONI FRUIT FERMENTJanuary 2022September 2023Allow2011NoNo
17568390NUTRITION-BASED METHOD FOR MANAGING ANIMAL BEHAVIORJanuary 2022January 2024Abandon2511YesNo
17285066SKIN WHITENING, ANTI-BACTERIAL OR ANTI-ATOPIC COMPOSITION, CONTAINING SYZYGIUM FORMOSUM EXTRACT AS ACTIVE INGREDIENTJanuary 2022August 2025Abandon5210YesNo
17623298Composition for Improving or Maintaining Quality of LifeDecember 2021February 2026Abandon4930NoNo
17560772USE OF GINSENG ALCOHOL EXTRACT IN SLEEP-PROMOTING HEALTH CARE PRODUCTS OR FOODSDecember 2021January 2024Allow2421YesNo
17621743COMPOSITION COMPRISING EXOSOMES DERIVED FROM INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL PROGENITOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITISDecember 2021February 2026Allow4930YesNo
17557250Oral Cannabis Substance and Method of Making Such SubstanceDecember 2021January 2024Abandon2510NoNo
17555028TONGKAT ALI EXTRACT PRODUCTION PROCESSES AND USES THEREOFDecember 2021December 2022Abandon1110NoNo
17553503PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTING, AMELIORATING OR TREATING DIABETES CONTAINING WASP EXTRACT AS ACTIVE INGREDIENTDecember 2021February 2024Abandon2610NoNo
17619617METHOD FOR EXTRACTION OF A RAW MATERIAL TO PRODUCE A FORMULATION RICH IN PHYTOCHEMICALSDecember 2021May 2025Abandon4110NoNo
17545768COMPOSITIONS HAVING THE ABILITY TO PROMOTE HEALTHY CHOLESTEROL LEVELSDecember 2021August 2023Abandon2001NoNo
17457937METHOD FOR EXTRACTION OF AN AGENT FROM A PLANT SOURCEDecember 2021February 2025Abandon3801NoNo
17540766INHIBITION OF SARS-CoV-2 VIRUS BY ARUM PALAESTINUMDecember 2021March 2024Abandon2721NoNo
17540810FORMULATIONS INHIBITING SARS-CoV-2 VIRUSDecember 2021April 2024Abandon2821NoNo
17536979COMPOSITIONS AND METHODS FOR INCREASING THE BIOAVAILABILITY OF ONE OR MORE COMPOUNDSNovember 2021February 2025Abandon3810NoNo
17536877COSMETIC COMPOSITION FOR ANTIOXIDANT OR SKIN INFLAMMATION IMPROVEMENT CONTAINING EUPHORBIA SUPINA EXTRACTNovember 2021January 2024Abandon2611NoNo
17613799NUTRITIONAL COMPOSITIONNovember 2021March 2026Allow5121NoYes
17526296ANTHOCYANIN POWDER EXTRACT AND PROCESS FOR PRODUCTIONNovember 2021September 2023Allow2210YesNo
17452029HEMP COMPOSITIONS AND METHODS OF MAKING THE SAMEOctober 2021December 2024Abandon3721NoNo
17604841PHARMACEUTICAL COMPOSITION COMPRISING MIXTURE EXTRACT OF COPTIS RHIZOME AND SCHIZONEPETA TENUIFOLIA AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASEOctober 2021October 2024Abandon3501NoNo
17438020PLANT-DERIVED EXTRACELLULAR VESICLE (EVS) COMPOSITIONS AND USES THEREOFSeptember 2021January 2026Abandon5221NoNo
17467319Therapeutic Mixture with Oregano Oil for Herpes InfectionsSeptember 2021October 2023Abandon2511NoNo
17466139USE OF HEMOLYMPH OR HEMOLYMPH COMPONENTS TO REGENERATE, REPAIR AND RESTORE THE SKIN BARRIERSeptember 2021June 2025Allow4541NoNo
17460262PHARMACEUTICAL COMPOSITION COMPRISING THE EXTRACT OF CANNABIS SATIVA AS AN EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING OF OBESITYAugust 2021February 2024Abandon3020NoNo
17407004SUPPLEMENT THAT ENHANCES INTRACELLULAR CONCENTRATION OF BIOACTIVE MOLECULES THROUGH INHIBITION OF MULTIDRUG RESISTANT (MDR) EFFLUX PUMPSAugust 2021June 2023Abandon2201NoNo
17406500BUTTER PREPARATION PROCESSAugust 2021February 2025Allow4231YesNo
17401594METHOD AND APPARATUS FOR PRODUCING CANNABIS SMOKE RESINAugust 2021December 2024Abandon4021NoNo
17395491Prevention and Treatment of SARS-CoV-2 Infection by the combination of Mentha piperita 1.. and Flos chrysanthemi 1.. ExtractsAugust 2021September 2025Abandon4941NoNo
17427380METHODS OF TREATING CANCER USING A COMBINATION OF TUMOR MEMBRANE VESICLES AND METFORMINJuly 2021October 2024Abandon3910NoNo
17421714Anticancer Activity of Buddleja Saligna CompositionsJuly 2021May 2025Allow4621YesNo
17365035BITTER GANODERMA LUCIDUM SPORE POWDER AND PREPARATION METHOD THEREOFJuly 2021August 2023Allow2510NoNo
17364996PROCESS FOR PRESERVING THE HUSK AND USE OF RAMBUTAN (NEPHELIUM LAPPACEUM) IN FOOD PRODUCTSJuly 2021September 2023Abandon2611NoNo
17362707COMPOSITION FOR TREATING VITILIGOJune 2021January 2024Abandon3020YesNo
17358553SYSTEMS AND METHODS FOR PRODUCING A KAVA LIQUID DIETARY SUPPLEMENTJune 2021December 2023Abandon2911NoNo
17353956PROBIOTIC SKIN FORMULATIONSJune 2021May 2024Allow3541YesNo
17416567A NUTRITIONAL COMPOSITION COMPRISING METABOLITES OF HMOS TO IMPROVE THE GASTROINTESTINAL BARRIERJune 2021January 2026Abandon5540NoNo
17416881BIOLOGICALLY ACTIVE SUBSTANCE, METHOD FOR MANUFACTURING SAME AND USE THEREOF AS AN AGENT FOR PROTECTING A BIOLOGICAL TISSUEJune 2021April 2025Allow4531YesNo
17352259Method of Fermenting Soybeans or other Oil Crops by Edible and Medicinal FungiJune 2021May 2025Abandon4721NoNo
17352278COMPOSITIONS OF COFFEE BEAN PRODUCTS, WHOLE HEMP PRODUCTS AND L-THEANINEJune 2021June 2023Abandon2410NoNo
17414595TWO-DOSAGE-FORM ESSENCE AND PREPARATION METHOD THEREOFJune 2021October 2024Allow4011YesNo
17348011SYSTEMS AND METHODS FOR TREATING A DYSBIOSIS USING FECAL-DERIVED BACTERIAL POPULATIONSJune 2021June 2023Abandon2401NoNo
17341064METHODS FOR FAT REDUCTION OR ELIMINATION OF LIPID DROPLETSJune 2021November 2022Allow1801YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOECKELMAN, JACOB A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.9%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
1
(20.0%)
Not Allowed After Appeal Filing
4
(80.0%)
Filing Benefit Percentile
24.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BOECKELMAN, JACOB A - Prosecution Strategy Guide

Executive Summary

Examiner BOECKELMAN, JACOB A works in Art Unit 1655 and has examined 207 patent applications in our dataset. With an allowance rate of 31.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner BOECKELMAN, JACOB A's allowance rate of 31.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BOECKELMAN, JACOB A receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BOECKELMAN, JACOB A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +49.1% benefit to allowance rate for applications examined by BOECKELMAN, JACOB A. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.2% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.4% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 108.1% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.